PD-1 Blockade + Dendritic Cell Fusion Vaccine + CT-011 for Multiple Myeloma
Trial Summary
What is the purpose of this trial?
The purpose of this research study is to determine the safety of CT-011 alone, as well as the combination of the Dendritic cell fusion vaccine and CT-011, after autologous stem cell transplantation (ASCT). We are also trying to find out what effect the combination has on the disease, including if it is more successful in preventing or delaying the disease from coming back, compared to treatment with autologous transplantation alone. ASCT is a standard therapy for multiple myeloma that is often successful in significantly decreasing the amount of cancer in the body. CT-011 is an investigational monoclonal antibody. Monoclonal antibodies are a type of drug given by infusion into a vein and are known to target specific cells (in this case, cells in the immune system). The dendritic cell fusion vaccine is an investigational agent that tries to help the immune system to recognize and fight against cancer cells. Unlike a standard vaccine that is used to prevent infections, cancer vaccines are being studied to see if they can fight cancers that are already in the body.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment PD-1 Blockade + Dendritic Cell Fusion Vaccine + CT-011 for Multiple Myeloma?
Research shows that the combination of CT-011, an anti-PD-1 antibody, with a dendritic cell/myeloma fusion vaccine can enhance the immune response in patients with multiple myeloma by activating T-cells, which are crucial for fighting cancer. Additionally, blocking the PD-1/PD-L1 pathway has been shown to improve survival in myeloma models, suggesting that this approach may help the immune system better target and destroy cancer cells.12345
Is the combination of PD-1 Blockade, Dendritic Cell Fusion Vaccine, and CT-011 generally safe for humans?
The combination of PD-1 blockade with CT-011 and dendritic cell fusion vaccine has been studied in multiple myeloma, showing enhanced immune responses without specific safety concerns mentioned in the provided studies. However, caution is advised as combining checkpoint inhibitors with certain drugs increased the risk of death in myeloma patients, highlighting the need for careful monitoring.12467
How is the treatment with PD-1 Blockade, Dendritic Cell Fusion Vaccine, and CT-011 unique for multiple myeloma?
This treatment is unique because it combines a vaccine made from a patient's own tumor cells and immune cells (dendritic cells) with CT-011, an antibody that blocks PD-1, a protein that can suppress the immune system. This combination aims to enhance the body's immune response against multiple myeloma by activating T-cells to better recognize and attack cancer cells.128910
Research Team
David Avigan, MD
Principal Investigator
Beth Israel Deaconess Medical Center
Eligibility Criteria
This trial is for adults over 18 with multiple myeloma who are candidates for high-dose chemotherapy and stem cell rescue. They must have a certain level of heart function, specific lab results, measurable disease, and no serious illnesses like significant heart disease or active infections. Pregnant women or those with autoimmune diseases (except stable hypothyroidism) can't join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Initial Therapy and Stem Cell Transplantation
Participants receive standard therapy to reduce multiple myeloma cells, followed by high dose chemotherapy and autologous stem cell transplantation
Treatment
Participants receive 3 infusions of CT-011 at 6 week intervals. Group 2 also receives Dendritic Cell Fusion Vaccine one week after each CT-011 infusion
Follow-up
Participants are monitored with blood tests, urine tests, bone marrow aspirate/biopsy, and skeletal survey at one, three, and six months following the last study treatment
Treatment Details
Interventions
- CT-011
- Dendritic Cell Fusion Vaccine
Find a Clinic Near You
Who Is Running the Clinical Trial?
Beth Israel Deaconess Medical Center
Lead Sponsor
United States Department of Defense
Collaborator
Brigham and Women's Hospital
Collaborator
Dana-Farber Cancer Institute
Collaborator
Rambam Health Care Campus
Collaborator
Gateway for Cancer Research
Collaborator